How Green Cross Health Limited makes money

Where GXH’s revenue went in FY2024: operating costs, depreciation, interest and tax, and what was left as net profit. Built from the income statement in the filed annual report, and drawn only when the figures reconcile with each other. GXH company profile

How Green Cross Health Limited makes money — FY2024

Revenue $503.9m · EBITDA $52.3m (10.4% of revenue) · Net profit $15.6m (3.1% of revenue) · Balance date 31 March 2024

Green Cross Health Limited (GXH) FY2024: where revenue of $503.9m wentRevenue → EBITDA: $52.3mRevenue → Operating costs (net of other income): $451.6mEBITDA → EBIT: $31.8mEBITDA → Depreciation & amortisation: $20.5mEBIT → Net profit: $15.6mEBIT → Interest: $10.3mEBIT → Income tax: $6.0mOther items (net gain) → Income tax: $624kRevenue: $503.9mRevenue$503.9mEBITDA: $52.3mEBITDA$52.3mOperating costs (net of other income): $451.6m (derived)Operating costs (net ofother income)$451.6m · derivedEBIT: $31.8mEBIT$31.8mDepreciation & amortisation: $20.5mDepreciation &amortisation$20.5mOther items (net gain): $624k (balancing item)Other items (net gain)$624k · balancingNet profit: $15.6mNet profit$15.6mInterest: $10.3mInterest$10.3mIncome tax: $6.6mIncome tax$6.6m

Band widths are proportional to NZD amounts. Dashed outlines mark derived figures; the hatched node is a balancing item (net profit less every line above it).

Green Cross Health Limited FY2024 figures used in the chart
FY2024AmountStatusNote
Revenue$503.9mReported
Operating costs (net of other income)−$451.6mDerived *Reported operating expenses $233.6m do not reconcile; not used.
EBITDA$52.3mReported
Depreciation & amortisation−$20.5mReported
EBIT$31.8mReported
Interest (net finance costs)−$10.3mReported
Income tax−$6.6mReported
Other items (net gain)+$624kBalancing item *Net profit less the lines above; covers fair-value movements, impairments, associates and anything else not itemised.
Net profit$15.6mReported
  • * operating costs: $451.6m = Revenue − EBITDA
Checks run on these figures (6)
  • Passed: Revenue is within the scale of a column stored in thousands.
  • Passed: Revenue in the income statement ($503.9m) vs the summary table ($503.9m): agree within 2%.
  • Passed: EBITDA − D&A = $31.8m vs reported EBIT $31.8m: reconciles.
  • Not met: Reported operating expenses ($233.6m) leave $270.3m, not EBITDA of $52.3m (gap $218m); costs derived as revenue minus operating profit instead. No split is shown.
  • Passed: Balancing item $0.6m is 0.1% of revenue (limit 25%).
  • Not met: Operating segments sum to $523.8m, 3.9% away from revenue of $503.9m (limit 2%); shown as one Revenue figure.

Figures extracted automatically from the annual report; check against the report. NZD thousands as stored, shown in millions. Source: annual_report_pdf · method: claude_haiku_pdf · extracted 7 March 2026.

Annual report: Green Cross Health Limited 2024 Annual Report (PDF, NZX)

EBITDA bridge, FY2023 → FY2024

What moved EBITDA between the two years: the change in revenue, less the change in operating costs (revenue less EBITDA, net of other income; not a reported line). The costs are one net figure; no split by type is held, so none is shown.

GXH EBITDA bridge FY2023 to FY2024FY2023 EBITDA: $56.4m$56.4mFY2023 EBITDARevenue change: +$10.3m+$10.3mRevenue changeCost change (derived): −$14.4m−$14.4mCost change (derived)FY2024 EBITDA: $52.3m$52.3mFY2024 EBITDA
GXH EBITDA bridge FY2023 to FY2024: figures
StepFY2023FY2024Effect on EBITDAStatus
FY2023 EBITDA$56.4m$56.4mAs charted
Revenue$493.6m$503.9m+$10.3mReported
Operating costs (net, derived)$437.2m$451.6m−$14.4mDerived: revenue − EBITDA
FY2024 EBITDA$52.3m$52.3mAs charted

$56.4m +$10.3m −$14.4m = $52.3m, which equals FY2024 EBITDA of $52.3m. EBITDA is the figure stored from each statement; companies that headline an adjusted measure (EBITDAF, underlying EBITDA) can report a different number.

What changed from FY2023 to FY2024

MeasureFY2023FY2024ChangeChange %
Revenue$493.6m$503.9m+$10.3m+2.1%
EBITDA$56.4m$52.3m−$4.1m−7.2%
Net profit$50.5m$15.6m−$35.0m−69.2%
EBITDA margin11.4%10.4%−1.0 pts—
Net margin10.2%3.1%−7.2 pts—

Both years passed the same checks. Margins are shares of revenue; their change is in percentage points. n/m = not meaningful (prior-year figure at or below zero). Each year holds the figures from its own annual report; restated comparatives are not applied.

Margins over time

EBITDA, EBIT and net profit as a share of revenue for each year whose figures passed the checks (8 of 10 years from FY2017). The shaded line is the median of 11 other listed Healthcare operating companies, using each one’s same financial year where it passed the checks; the number of companies in each median is in the table. Gaps are years that were not charted.

EBITDA margin
GXH ebitda margin by financial year, with peer median0%20%40%FY17FY18FY20FY22FY24FY26FY2017: not charted — not from annual reportFY2018: not charted — not from annual reportFY2019: GXH 9.0%; peer median 14.4% (3)FY2020: GXH 9.7%; peer median 8.9% (3)FY2021: GXH 7.6%; peer median 19.1% (3)FY2022: GXH 11.8%; peer median 28.3% (4)FY2023: GXH 11.4%; peer median 15.0% (5)FY2024: GXH 10.4%; peer median 13.4% (7)FY2025: GXH 9.3%; peer median 15.0% (6)FY2026: GXH 9.2%; peer median 12.4% (2)
EBIT margin
GXH ebit margin by financial year, with peer median0%20%40%FY17FY18FY20FY22FY24FY26FY2017: not charted — not from annual reportFY2018: not charted — not from annual reportFY2019: GXH 6.9%; peer median 9.6% (4)FY2020: GXH 5.5%; peer median 20.1% (5)FY2021: GXH 6.2%; peer median 9.7% (5)FY2022: GXH 8.1%; peer median 24.0% (4)FY2023: GXH 6.9%; peer median 11.5% (5)FY2024: GXH 6.3%; peer median 10.8% (7)FY2025: GXH 8.3%; peer median 13.2% (6)FY2026: GXH 8.3%; peer median 8.3% (2)
Net margin
GXH net margin by financial year, with peer median0%20%40%FY17FY18FY20FY22FY24FY26FY2017: not charted — not from annual reportFY2018: not charted — not from annual reportFY2019: GXH 3.9%; peer median 13.0% (4)FY2020: GXH 3.0%; peer median 12.0% (5)FY2021: GXH 3.7%; peer median 2.0% (5)FY2022: GXH 5.0%; peer median 16.5% (4)FY2023: GXH 10.2%; peer median 2.9% (5)FY2024: GXH 3.1%; peer median 6.2% (7)FY2025: GXH 3.1%; peer median 14.4% (6)FY2026: GXH 4.7%; peer median 5.1% (2)

GXH   peer median   below the axis: year not charted (reason in the table). All panels share one scale.

GXH margins by year with peer medians
YearEBITDA margin: GXH · peer median (n)EBIT margin: GXH · peer median (n)Net margin: GXH · peer median (n)Note
FY2017—— (1)—33.0% (2)—22.5% (2)Not charted: not from annual report
FY2018—8.6% (3)—16.6% (4)—11.6% (4)Not charted: not from annual report
FY20199.0%14.4% (3)6.9%9.6% (4)3.9%13.0% (4)
FY20209.7%8.9% (3)5.5%20.1% (5)3.0%12.0% (5)
FY20217.6%19.1% (3)6.2%9.7% (5)3.7%2.0% (5)
FY202211.8%28.3% (4)8.1%24.0% (4)5.0%16.5% (4)
FY202311.4%15.0% (5)6.9%11.5% (5)10.2%2.9% (5)
FY202410.4%13.4% (7)6.3%10.8% (7)3.1%6.2% (7)
FY20259.3%15.0% (6)8.3%13.2% (6)3.1%14.4% (6)
FY20269.2%12.4% (2)8.3%8.3% (2)4.7%5.1% (2)

Peer medians use only peer-years that passed the same checks; a median of fewer than two companies is not shown. Years are grouped by financial-year label, and year-end months differ between companies.

Not yet available: where the cash goes (operating cash flow to capex, dividends and debt) and underlying versus reported earnings. The figures they need are not yet validated.

Years not charted

These years are on file but their figures did not pass the checks, so no chart is drawn for them.

  • FY2018: Figures were not read from a filed annual report (source: not recorded).
  • FY2017: Figures were not read from a filed annual report (source: not recorded).

All companies with a chart

Data sourced from NZX company annual reports (income statements). Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz.

For informational purposes only. Not investment advice.

Get NZX governance insights in your inbox

Weekly digest of board changes, insider trades, and market signals. No spam. Unsubscribe anytime.